News
Changes to conventional cohort eligibility criteria
As part of the 14th Substantial Amendment for the study, there have been some changes to the eligibility criteria for patients on conventional treatments. The implementation date for Substantial Amendment 14 is 08/05/2025; these changes will affect any patients...
Amendment 14
Study Amendment 14 to BADBIR has an implementation date of 8th May 2025.Documents in this amendmentYou can download all of the files for this amendment in one go using the link below (.zip file). If you would like the tracked changes versions of the documents to see...
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, Catherine H Smith, Richard B Warren, Christopher E M Griffiths, BADBIR study group British Journal of Dermatology, ljaf017, https://doi.org/10.1093/bjd/ljaf017 Related Contact Us Tel: +44...
Taltz (ixekizumab) recruitment has restarted
If a patient recently started on Taltz meets all of our eligibility criteria, they can be recruited.We will review patients who switched from the Conventional cohort onto Taltz, where we have paused their cohort; these patients will now be able to be switched.Please...
BADBIR Annual Update 2024
Welcome to the 2024 BADBIR Update. Led by the British Association of Dermatologists and co-ordinated at the University of Manchester, since 2007 BADBIR has grown to be a leading source of real-world data for researching psoriasis therapies.While we prepare this...
Taltz (ixekizumab) recruitment will end on 31st July 2024
Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...
BADBIR will be at the BAD Annual Meeting in Manchester, 2nd-4th July
BADBIR will be at the BAD Annual Meeting in Manchester, 2nd-4th JulyCome and visit us on our stand in the exhibition hall, or attend one of our talks:Tues 2nd July; 14:30-15:00: How BADBIR can help answer your research questionWeds 3rd July; 09:00-09:15: The...
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
Duc Binh Phan, Anthony P Bewley, Catherine H Smith, Teena Mackenzie, Christopher E M Griffiths, Mark Lunt, Richard B Warren, Zenas Z N Yiu British Journal of Dermatology, Volume 189, Issue 1, July 2023, Pages 62–70, https://doi.org/10.1093/bjd/ljad107Published: 05...
Centre of the month: June 2024
Hull University Teaching Hospitals NHS Trust was selected for their hard work resolving queries and getting patients up-to-date. A message from Hull: BADBIR has shown how effective team working helps clinicians and patients provide safe and quality care for our...
Centre of the month: February 2024
Ashford and St Peter's NHS Foundation Trust was selected for their hard work keeping on top of outstanding follow-ups. A message from Ashford and St Peter's: We are really proud to have been selected as the BADBIR centre of the month. Our team has worked really hard...